CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Immunosuppression +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00029393
NCT00029393Phase 2Completed
CompareCT.gov

Induction of Stable Chimerism for Sickle Cell Anemia

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Jan 11, 2002·Updated Jul 29, 2016

In Brief

A Phase 2 clinical trial evaluating Hematopoietic Stem Cell Transplantation and Immunosuppression for Blood Disease and 2 related conditions. Completed.

Detailed Summary

To investigate a modified hematopoeitic cell transplantation (HCT) procedure for sickle cell disease that significantly reduces the toxicity of HCT, yet retains its therapeutic benefit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Disease, Hematopoietic Stem Cell Transplantation, Anemia, Sickle Cell
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2002
Enrollment StartAug 1, 2001
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 24.5 years ago

Interventions

Hematopoietic Stem Cell Transplantationprocedure

Immunosuppressiondrug